NOSH-aspirin (NBS-1120) inhibits pancreatic cancer cell growth in a xenograft mouse model: Modulation of FoxM1, p53, NF-κB, iNOS, caspase-3 and ROS.

[1]  N. Chandel,et al.  The Two Faces of Reactive Oxygen Species in Cancer , 2017 .

[2]  F. Jiao,et al.  Prognostic value and clinicopathological features of PD-1/PD-L1 expression with mismatch repair status and desmoplastic stroma in Chinese patients with pancreatic cancer , 2016, Oncotarget.

[3]  A. Schetter,et al.  Inducible nitric oxide synthase enhances disease aggressiveness in pancreatic cancer , 2016, Oncotarget.

[4]  Ke Chen,et al.  Reactive Oxygen Species and Targeted Therapy for Pancreatic Cancer , 2016, Oxidative medicine and cellular longevity.

[5]  K. Kashfi,et al.  NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid has enhanced chemo-preventive properties compared to aspirin, is gastrointestinal safe with all the classic therapeutic indications. , 2015, Biochemical pharmacology.

[6]  K. Kashfi,et al.  The dual role of iNOS in cancer☆ , 2015, Redox biology.

[7]  M. Singer,et al.  Key bioactive reaction products of the NO/H2S interaction are S/N-hybrid species, polysulfides, and nitroxyl , 2015, Proceedings of the National Academy of Sciences.

[8]  M. Hidalgo,et al.  Pancreatic cancer: from state-of-the-art treatments to promising novel therapies , 2015, Nature Reviews Clinical Oncology.

[9]  M. Kelm,et al.  On the chemical biology of the nitrite/sulfide interaction. , 2015, Nitric oxide : biology and chemistry.

[10]  N. Chandel,et al.  ROS-dependent signal transduction. , 2015, Current opinion in cell biology.

[11]  Ralph H. Hruban,et al.  Genomic Landscapes of Pancreatic Neoplasia , 2015, Journal of pathology and translational medicine.

[12]  Michael V. Gormally,et al.  Suppression of the FOXM1 transcriptional program via novel small molecule inhibition , 2014, Nature Communications.

[13]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[14]  K. Xie,et al.  FOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis. , 2014, Biochimica et biophysica acta.

[15]  S. K. Choudhuri,et al.  ROS and RNS induced apoptosis through p53 and iNOS mediated pathway by a dibasic hydroxamic acid molecule in leukemia cells. , 2014, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[16]  K. Kashfi,et al.  Hydrogen sulfide-releasing aspirin inhibits the growth of leukemic Jurkat cells and modulates β-catenin expression. , 2013, Leukemia research.

[17]  K. Kashfi,et al.  Abstract 4793: NOSH-aspirin inhibits breast cancer cell growth: an effect modulated through reactive oxygen species and independent of the ER status. , 2013 .

[18]  M. Barbacid,et al.  EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. , 2012, Cancer cell.

[19]  S. Lippard,et al.  Chemical Characterization of the Smallest S-Nitrosothiol, HSNO; Cellular Cross-talk of H2S and S-Nitrosothiols , 2012, Journal of the American Chemical Society.

[20]  K. Kashfi,et al.  NOSH-aspirin (NBS-1120), a novel nitric oxide- and hydrogen sulfide-releasing hybrid is a potent inhibitor of colon cancer cell growth in vitro and in a xenograft mouse model. , 2012, Biochemical and biophysical research communications.

[21]  A. Barsegian,et al.  Hydrogen sulfide-releasing aspirin suppresses NF-κB signaling in estrogen receptor negative breast cancer cells in vitro and in vivo. , 2012, Biochemical pharmacology.

[22]  K. Kashfi,et al.  Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. , 2012, Biochemical pharmacology.

[23]  K. Kashfi,et al.  NOSH-Aspirin: A Novel Nitric Oxide-Hydrogen Sulfide-Releasing Hybrid: A New Class of Anti-inflammatory Pharmaceuticals. , 2012, ACS medicinal chemistry letters.

[24]  M. Marra,et al.  Gemcitabine/cannabinoid combination triggers autophagy in pancreatic cancer cells through a ROS-mediated mechanism , 2011, Cell Death and Disease.

[25]  M. Hirota,et al.  Nitric Oxide Inhibits the Proliferation and Invasion of Pancreatic Cancer Cells through Degradation of Insulin Receptor Substrate-1 Protein , 2010, Molecular Cancer Research.

[26]  K. Xie,et al.  Nitric oxide and pancreatic cancer pathogenesis, prevention, and treatment. , 2010, Current pharmaceutical design.

[27]  A. Barsotti,et al.  Pro-proliferative FoxM1 is a target of p53-mediated repression , 2009, Oncogene.

[28]  A. Gartel,et al.  p53 negatively regulates expression of FoxM1 , 2009, Cell cycle.

[29]  S. Fiorucci.  Prevention of nonsteroidal anti-inflammatory drug-induced ulcer: looking to the future. , 2009, Gastroenterology clinics of North America.

[30]  A. Scarpa,et al.  Intracellular zinc increase inhibits p53(-/-) pancreatic adenocarcinoma cell growth by ROS/AIF-mediated apoptosis. , 2009, Biochimica et biophysica acta.

[31]  I. Wierstra,et al.  FOXM1, a typical proliferation-associated transcription factor , 2007, Biological chemistry.

[32]  Zhiwei Wang,et al.  Down-regulation of Forkhead Box M1 transcription factor leads to the inhibition of invasion and angiogenesis of pancreatic cancer cells. , 2007, Cancer research.

[33]  Michael S Janes,et al.  Selective fluorescent imaging of superoxide in vivo using ethidium-based probes , 2006, Proceedings of the National Academy of Sciences.

[34]  K. Coombes,et al.  Identification of Cell Cycle Regulatory Genes as Principal Targets of p53-mediated Transcriptional Repression* , 2006, Journal of Biological Chemistry.

[35]  Jianjun Gao,et al.  Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model. , 2006, Cancer research.

[36]  D. D. Hoff.  What's new in pancreatic cancer treatment pipeline? , 2006 .

[37]  K. Kashfi,et al.  Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention. , 2005, Biochemical pharmacology.

[38]  M. Follettie,et al.  Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. , 2005, Cancer research.

[39]  R. Costa.  FoxM1 dances with mitosis , 2005, Nature Cell Biology.

[40]  Hans Clevers,et al.  FoxM1 is required for execution of the mitotic programme and chromosome stability , 2005, Nature Cell Biology.

[41]  K. Kashfi,et al.  NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression. , 2004, Biochemical and biophysical research communications.

[42]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[43]  N. Chandler,et al.  Increased expression of NF-κB subunits in human pancreatic cancer cells1,2 ☆ , 2004 .

[44]  M. Löhr,et al.  A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform , 2003, Virchows Archiv.

[45]  F. Traganos,et al.  Nitric Oxide-Donating Nonsteroidal Anti-Inflammatory Drugs Inhibit the Growth of Various Cultured Human Cancer Cells: Evidence of a Tissue Type-Independent Effect , 2002, Journal of Pharmacology and Experimental Therapeutics.

[46]  J. Wallace,et al.  Nitric oxide in mucosal defense: a little goes a long way. , 2000, Gastroenterology.

[47]  T. Vanden Hoek,et al.  Generation of superoxide in cardiomyocytes during ischemia before reperfusion. , 1999, American journal of physiology. Heart and circulatory physiology.

[48]  P. Maher,et al.  The Regulation of Reactive Oxygen Species Production during Programmed Cell Death , 1998, The Journal of cell biology.

[49]  V. Ferrans,et al.  Requirement for Generation of H2O2 for Platelet-Derived Growth Factor Signal Transduction , 1995, Science.

[50]  H. Ischiropoulos,et al.  Evaluation of the probe 2',7'-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress. , 1992, Chemical research in toxicology.

[51]  M. Seeds,et al.  Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. , 1983, Journal of immunology.

[52]  E. Lam,et al.  FOXM1: From cancer initiation to progression and treatment. , 2012, Biochimica et biophysica acta.

[53]  K. Kashfi.  Anti-inflammatory agents as cancer therapeutics. , 2009, Advances in pharmacology.

[54]  René H Medema,et al.  FoxM1: at the crossroads of ageing and cancer. , 2007, Biochimica et biophysica acta.

[55]  N. Chandler,et al.  Increased expression of NF-kappa B subunits in human pancreatic cancer cells. , 2004, The Journal of surgical research.

[56]  J. Abbruzzese,et al.  A novel, clinically relevant animal model of metastatic pancreatic adenocarcinoma biology and therapy , 2001, International journal of gastrointestinal cancer.

[57]  Douglas B. Evans,et al.  The Nuclear Factor-κB RelA Transcription Factor Is Constitutively Activated in Human Pancreatic Adenocarcinoma Cells , 1999 .

[58]  J. Abbruzzese,et al.  The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.